{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:24:29Z","timestamp":1791822269436,"version":"4.3.4"},"reference-count":44,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Constitutive activation of the nuclear factor-kappaB (NF-\u03baB) pathway has been shown to be involved in the resistance of tumor cells to apoptosis in several human malignancies of the hematopoietic lineage. By using electrophoretic mobility shift assay (EMSA) and confocal microscopic analysis, we demonstrate that NF-\u03baB is constitutively activated in cutaneous T-cell lymphoma (CTCL) cell lines HuT-78, MyLa, and SeAx and in peripheral blood lymphocytes (PBLs) from patients with Se\u0301zary syndrome (SS) presenting a high ratio of tumor cells, with evidence of p50 and RelA\/p65 in DNA-linked complexes. Transfection of SeAx line with a \u03baB\/luciferase reporter plasmid showed that translocated NF-\u03baB complexes were functional. Selective inhibition of NF-\u03baB, by transfecting CTCL cell lines with a super-repressor form of I\u03baB\u03b1, led to apoptosis. We evidenced down-regulation of NF-\u03baB activation and induction of CTCL cell apoptosis in the presence of proteasome 26S inhibitors ALLN, MG132, and bortezomib. Bortezomib at nanomolar concentrations inhibited constitutive activation of NF-\u03baB and induced apoptosis of CTCL cells, with evidence of an upregulation of Bax expression. These results demonstrate the key role played by NF-\u03baB in the resistance of CTCL to apoptosis and suggest that bortezomib might be useful for the treatment of patients with advanced stages of CTCL refractory to standard antineoplastic chemotherapy.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2536","type":"journal-article","created":{"date-parts":[[2005,10,12]],"date-time":"2005-10-12T03:23:24Z","timestamp":1129087404000},"page":"2354-2363","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["Down-regulating constitutive activation of the NF-\u03baB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis"],"prefix":"10.1182","volume":"107","author":[{"given":"Aurore","family":"Sors","sequence":"first","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francette","family":"Jean-Louis","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pellet","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Laroche","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Dubertret","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Courtois","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve\u0301","family":"Bachelez","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Michel","sequence":"additional","affiliation":[{"name":"From the Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U697, Skin Research Institute and Department of Dermatology 1, Ho\u0302pital Saint-Louis, Paris, France; and the Department of Immuno-Dermatology, Ho\u0302pital Avicenne, Bobigny, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711162158700_REF1","doi-asserted-by":"crossref","unstructured":"Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood.1996;88: 2385-2409.","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385"},{"key":"2019111711162158700_REF2","doi-asserted-by":"crossref","unstructured":"Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest.2005;115: 798-812.","DOI":"10.1172\/JCI24826"},{"key":"2019111711162158700_REF3","doi-asserted-by":"crossref","unstructured":"Edelson R, Berger C, Raafat J, Warburton D. Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. J Invest Dermatol.1979;73: 548-550.","DOI":"10.1111\/1523-1747.ep12541543"},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Edelson R. Cutaneous T cell lymphoma (mycosis fungoides, Se\u0301zary syndrome and other variants). J Am Acad Dermatol.1980;2: 89-106.","DOI":"10.1016\/S0190-9622(80)80385-9"},{"key":"2019111711162158700_","unstructured":"Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol.1990;136: 1053-1068."},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Broder S, Edelson RL, Lutzner MA, et al. The Sezary syndrome: a malignant proliferation of helper T cells. J Clin Invest.1976;58: 1297-1306.","DOI":"10.1172\/JCI108585"},{"key":"2019111711162158700_REF7","doi-asserted-by":"crossref","unstructured":"Berger CL, Warburton D, Raafat J, Logerfo P, Edelson RL. Cutaneous T cell lymphoma: neoplasm of T cells with helper activity. Blood.1979;53: 642-651.","DOI":"10.1182\/blood.V53.4.642.642"},{"key":"2019111711162158700_REF8","doi-asserted-by":"crossref","unstructured":"Kaye FJ, Bunn PJ, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med.1989;321: 1784-1790.","DOI":"10.1056\/NEJM198912283212603"},{"key":"2019111711162158700_REF9","doi-asserted-by":"crossref","unstructured":"Ingen-Housz-Oro S, Bussel A, Flageul B, et al. Follow-up of the T-cell clonality in Sezary patients treated by extracorporeal photopheresis using a new assay: the immunoscope technique. Transfus Apheresis Sci.2003;28: 35-42.","DOI":"10.1016\/S1473-0502(02)00098-8"},{"key":"2019111711162158700_REF10","doi-asserted-by":"crossref","unstructured":"Michel L, Dupuy A, Jean-Louis F, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol.2003;121: 881-893.","DOI":"10.1046\/j.1523-1747.2003.12479.x"},{"key":"2019111711162158700_REF11","doi-asserted-by":"crossref","unstructured":"Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-\u03baB activity. Annu Rev Immunol.2000;18: 621-663.","DOI":"10.1146\/annurev.immunol.18.1.621"},{"key":"2019111711162158700_REF12","doi-asserted-by":"crossref","unstructured":"Roff M, Thompson J, Rodriguez MS, et al. Role of I\u03baB\u03b1 ubiquitination in signal-induced activation of NF-\u03baB in vivo. J Biol Chem.1996;271: 7844-7850.","DOI":"10.1074\/jbc.271.13.7844"},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Henkel T, Machleidt T, Alkalay I, Kroenke M, BenNeriah Y, Baeuerle PA. Rapid proteolysis of I\u03baB\u03b1 is necessary for activation of transcription factor NF-\u03baB. Nature.1993;365: 182-185.","DOI":"10.1038\/365182a0"},{"key":"2019111711162158700_REF14","doi-asserted-by":"crossref","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell.1994;78: 773-785.","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"2019111711162158700_REF15","doi-asserted-by":"crossref","unstructured":"Zheng Y, Vig M, Lyons J, Van Parijs L, Beg AA. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med.2003;197: 861-874.","DOI":"10.1084\/jem.20021610"},{"key":"2019111711162158700_REF16","doi-asserted-by":"crossref","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells. J Exp Med.2001;194: 1861-1874.","DOI":"10.1084\/jem.194.12.1861"},{"key":"2019111711162158700_REF17","doi-asserted-by":"crossref","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol.2003;171: 88-95.","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"2019111711162158700_REF18","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-\u03baB blockade in multiple myeloma: therapeutic applications. Neoplasia.2002;99: 4079-4086."},{"key":"2019111711162158700_REF19","doi-asserted-by":"crossref","unstructured":"Izban KF, Ergin M, Qin JZ, et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol.2000;31: 1482-1490.","DOI":"10.1053\/hupa.2000.20370"},{"key":"2019111711162158700_REF20","unstructured":"Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.1999;59: 2615-2622."},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol.2001;28: 613-619.","DOI":"10.1016\/S0093-7754(01)90034-X"},{"key":"2019111711162158700_REF22","doi-asserted-by":"crossref","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer.2004;4: 349-360.","DOI":"10.1038\/nrc1361"},{"key":"2019111711162158700_REF23","unstructured":"Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res.2001;7: 1419-1428."},{"key":"2019111711162158700_REF24","unstructured":"Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res.2002;8: 2505-2511."},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol.2004;22: 2108-2121.","DOI":"10.1200\/JCO.2004.02.106"},{"key":"2019111711162158700_REF26","doi-asserted-by":"crossref","unstructured":"Nasr R, El-Sabban ME, Karam J-A, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia\/lymphoma. Oncogene.2005;24: 419-430.","DOI":"10.1038\/sj.onc.1208212"},{"key":"2019111711162158700_REF27","unstructured":"Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res.2001;61: 3071-3076."},{"key":"2019111711162158700_","doi-asserted-by":"crossref","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med.2003;348: 2609-2617.","DOI":"10.1056\/NEJMoa030288"},{"key":"2019111711162158700_REF29","doi-asserted-by":"crossref","unstructured":"Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol.2005;45: 465-476.","DOI":"10.1146\/annurev.pharmtox.45.120403.100037"},{"key":"2019111711162158700_REF30","doi-asserted-by":"crossref","unstructured":"Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castleman's disease. Blood.1995;86: 1131-1138.","DOI":"10.1182\/blood.V86.3.1131.1131"},{"key":"2019111711162158700_REF31","doi-asserted-by":"crossref","unstructured":"Gorochov G, Bachelez H, Cayuela JM, et al. Expression of V beta gene segments by Sezary cells. J Invest Dermatol.1995;105: 56-61.","DOI":"10.1111\/1523-1747.ep12312560"},{"key":"2019111711162158700_REF32","doi-asserted-by":"crossref","unstructured":"Bachelez H, Hadida F, Parizot C, et al. Oligoclonal expansion of HIV-specific cytotoxic CD8 T lymphocytes in the skin of HIV-1\u2013infected patients with cutaneous pseudolymphoma. J Clin Invest.1998;101: 2506-2516.","DOI":"10.1172\/JCI1450"},{"key":"2019111711162158700_REF33","doi-asserted-by":"crossref","unstructured":"Djavaheri-Mergny M, Marsac C, Mazie\u0300re C, et al. UV-A irradiation induces a decrease in the mitochondrial respiratory activity of human NCTC 2544 keratinocytes. Free Rad Res.2001;34: 583-594.","DOI":"10.1080\/10715760100300481"},{"key":"2019111711162158700_REF34","doi-asserted-by":"crossref","unstructured":"Whiteside ST, Ernst MK, LeBail O, Laurent-Winter C, Rice N, Israel A. N- and C-terminal sequences control degradation of MAD3\/I kappa B alpha in response to inducers of NF-kappa B activity. Mol Cell Biol.1995;15: 5339-5345.","DOI":"10.1128\/MCB.15.10.5339"},{"key":"2019111711162158700_REF35","unstructured":"Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood.1999;93: 2360-2368."},{"key":"2019111711162158700_REF36","doi-asserted-by":"crossref","unstructured":"Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood.2001;98: 2778-2783.","DOI":"10.1182\/blood.V98.9.2778"},{"key":"2019111711162158700_REF37","doi-asserted-by":"crossref","unstructured":"Xiao G, Cvijic ME, Fong A, et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2\/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J.2001;20: 6805-6815.","DOI":"10.1093\/emboj\/20.23.6805"},{"key":"2019111711162158700_REF38","doi-asserted-by":"crossref","unstructured":"Hironaka N, Mochida K, Mori N, Maeda M, Yamamoto N, Yamaoka S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia.2004;6: 266-278.","DOI":"10.1593\/neo.03388"},{"key":"2019111711162158700_REF39","doi-asserted-by":"crossref","unstructured":"Tracey L, Villuendas R, Dotor AM, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood.2003;102: 1042-1050.","DOI":"10.1182\/blood-2002-11-3574"},{"key":"2019111711162158700_REF40","doi-asserted-by":"crossref","unstructured":"Poszepczynska E, Bagot M, Echchakir H, et al. Functional characterization of an IL-7\u2013dependent CD4(+) CD8\u03b1\u03b1(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood.2000;96: 1056-1063.","DOI":"10.1182\/blood.V96.3.1056"},{"key":"2019111711162158700_REF41","doi-asserted-by":"crossref","unstructured":"Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev.1999;13: 1899-1911.","DOI":"10.1101\/gad.13.15.1899"},{"key":"2019111711162158700_REF42","doi-asserted-by":"crossref","unstructured":"Bentires-Alj M, Dejardin E, Viatour P, et al. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene.2001;20: 2805-2813.","DOI":"10.1038\/sj.onc.1204343"},{"key":"2019111711162158700_REF43","doi-asserted-by":"crossref","unstructured":"Grimm T, Schneider S, Naschberger E, et al. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood.2005;105: 3263-3269.","DOI":"10.1182\/blood-2004-07-2752"},{"key":"2019111711162158700_REF44","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood.2003;101: 1530-1534.","DOI":"10.1182\/blood-2002-08-2543"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2354\/1286379\/zh800606002354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/6\/2354\/1286379\/zh800606002354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T07:47:53Z","timestamp":1586504873000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/6\/2354\/22075\/Downregulating-constitutive-activation-of-the-NF%CE%BAB"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2536","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]}}}